Quadruple treatment: one step closer to optimal treatment of NDMM patients ineligible for ASCT?
Length: 01:58:00
The recording of the webinar, originally held on 12 March 2025, is now available on demand. The session explored advancements in the treatment of NDMM patients ineligible for ASCT, specifically relevant for hematologists.
Moderated by Dr. Fredrik Schjesvold, experts including Professor Salomon Manier, Professor Xavier Leleu, and Dr. Thomas Martin discussed patient care gaps, supporting studies, and considerations for selecting the right treatment approach.
Access the recording now to gain valuable insights and engage with the faculty’s expert discussion.
Scientific program
Welcome & introduction
(Dr. Fredrik Schjesvold (moderator))
Definition of the patient populations, treatment goals.
(Professor Salomon Manier)
Studies supporting quadruple treatment in NDMM non-transplant patients
(Professor Xavier Leleu)
Is quadruple treatment for all NDMM non-transplant patients? How to select the right patient for the right treatment (frailty and comorbidity)
(Dr. Thomas Martin)
Panel discussion and Q&A
Speakers
Dr. Fredrik Schjesvold
Hematologist,,
Head of Oslo Myeloma Center,
Norway
Prof. Salomon Manier
Professor of Hematology,
Lille University Hospital, ,
France
Prof. Xavier Leleu
Professor & Head of Myeloma Clinic and Head of Department of Hematology,
Hospital La Mileterie, Poitiers,,
France
Prof. Thomas Martin
Doctor & associate director of UCSF’s myeloma program and director of the unrelated donor transplantation programs for adults ,
UCSF Medical Center,
US
